These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 16738535)

  • 41. Erythropoietin in diabetic retinopathy.
    Reid G; Lois N
    Vision Res; 2017 Oct; 139():237-242. PubMed ID: 28652140
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Differential neuroprotective properties of endogenous and exogenous erythropoietin in a mouse model of traumatic brain injury.
    Shein NA; Grigoriadis N; Alexandrovich AG; Simeonidou C; Spandou E; Tsenter J; Yatsiv I; Horowitz M; Shohami E
    J Neurotrauma; 2008 Feb; 25(2):112-23. PubMed ID: 18260794
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Endogenous erythropoietin system in non-hematopoietic lineage cells plays a protective role in myocardial ischemia/reperfusion.
    Tada H; Kagaya Y; Takeda M; Ohta J; Asaumi Y; Satoh K; Ito K; Karibe A; Shirato K; Minegishi N; Shimokawa H
    Cardiovasc Res; 2006 Aug; 71(3):466-77. PubMed ID: 16781691
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Erythropoietin and engineered innate repair activators.
    Brines M; Cerami A
    Methods Mol Biol; 2013; 982():1-11. PubMed ID: 23456859
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection.
    Bogoyevitch MA
    Cardiovasc Res; 2004 Aug; 63(2):208-16. PubMed ID: 15249178
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Erythropoietin reduces ischemia-reperfusion injury in the rat liver.
    Schmeding M; Neumann UP; Boas-Knoop S; Spinelli A; Neuhaus P
    Eur Surg Res; 2007; 39(3):189-97. PubMed ID: 17377393
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Erythropoietin mediates terminal granulocytic differentiation of committed myeloid cells with ectopic erythropoietin receptor expression.
    Arcasoy MO; Maun NA; Perez L; Forget BG; Berliner N
    Eur J Haematol; 2001 Aug; 67(2):77-87. PubMed ID: 11722594
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo.
    Patel NS; Sharples EJ; Cuzzocrea S; Chatterjee PK; Britti D; Yaqoob MM; Thiemermann C
    Kidney Int; 2004 Sep; 66(3):983-9. PubMed ID: 15327391
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure.
    Nemoto T; Yokota N; Keane WF; Rabb H
    Kidney Int; 2001 Jan; 59(1):246-51. PubMed ID: 11135077
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Epo and non-hematopoietic cells: what do we know?
    Ogunshola OO; Bogdanova AY
    Methods Mol Biol; 2013; 982():13-41. PubMed ID: 23456860
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Spinal Cord Ischemia-Reperfusion Injury Induces Erythropoietin Receptor Expression.
    Foley LS; Fullerton DA; Bennett DT; Freeman KA; Mares J; Bell MT; Cleveland JC; Weyant MJ; Meng X; Puskas F; Reece TB
    Ann Thorac Surg; 2015 Jul; 100(1):41-6; discussion 46. PubMed ID: 25865765
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Overview of erythropoietin].
    Lacombe C; Mayeux P; Casadevall N
    Nephrologie; 1991; 12(5):221-6. PubMed ID: 1662784
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of erythropoietin in central and peripheral nerve injury.
    Lykissas MG; Korompilias AV; Vekris MD; Mitsionis GI; Sakellariou E; Beris AE
    Clin Neurol Neurosurg; 2007 Oct; 109(8):639-44. PubMed ID: 17624659
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Do non-hemopoietic effects of erythropoietin play a beneficial role in heart failure?
    Latini R; Brines M; Fiordaliso F
    Heart Fail Rev; 2008 Dec; 13(4):415-23. PubMed ID: 18236153
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Science review: recombinant human erythropoietin in critical illness: a role beyond anemia?
    Coleman T; Brines M
    Crit Care; 2004 Oct; 8(5):337-41. PubMed ID: 15469595
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The brain erythropoietin system and its potential for therapeutic exploitation in brain disease.
    Hasselblatt M; Ehrenreich H; Sirén AL
    J Neurosurg Anesthesiol; 2006 Apr; 18(2):132-8. PubMed ID: 16628067
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The potential role of erythropoietin as a pleiotropic agent in post-cardiac arrest syndrome.
    Xanthos T; Vasileiou PV; Kakavas S; Syggelou A; Iacovidou N
    Curr Pharm Des; 2011; 17(15):1517-29. PubMed ID: 21486214
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Promises and pitfalls in erythopoietin-mediated tissue protection: are nonerythropoietic derivatives a way forward?
    Hand CC; Brines M
    J Investig Med; 2011 Oct; 59(7):1073-82. PubMed ID: 20683348
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The extra-hematopoietic role of erythropoietin in diabetes mellitus.
    Choi D; Retnakaran R; Woo M
    Curr Diabetes Rev; 2011 Jul; 7(4):284-90. PubMed ID: 21644916
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Epo delivery by genetically engineered C2C12 myoblasts immobilized in microcapsules.
    Murua A; Orive G; Hernandez RM; Pedraz JL
    Adv Exp Med Biol; 2010; 670():54-67. PubMed ID: 20384218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.